Trial Profile
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor/VX-659 (Primary) ; Ivacaftor; Ivacaftor/tezacaftor
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Results presented in a Vertex Pharmaceuticals media release.
- 27 Nov 2018 Primary endpoint has been met. (Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)), according to a Vertex Pharmaceuticals media release.